Recurrence and survival outcomes of triple-negative breast cancer survivors disease-free at 5-years and relationship to low hormone receptor positivity (1-9% versus <1%).

Abstract

1077Background: We counsel our triple negative breast cancer (TNBC) patients that recurrence is highest in the first 5 years after diagnosis. There is limited data with extended follow-up on frequency, characteristics, and predictors of late events. Methods: The MD Anderson database was retrospectively queried for stage I-III TNBC survivors disease-free at 5 years. TNBC was defined as estrogen (ER) and progesterone (PR) receptors < 10% and HER-2/neu negative per previous guidelines. We collected demographic, tumor, treatment, and outcome data. Kaplan-Meier method was used to estimate yearly recurrence free survival (RFS), overall survival (OS), and recurrence free interval (RFI) as defined by STEEP criteria. RFI is time to recurrence without including death as an event. Cox proportional hazards model was used to assess effect of low hormone receptor positivity on outcomes. Results: 881 patients were disease free at 5 years from diagnosis with median follow-up of 8.2 years. Table 1 quantifies cumulative pr...